Navigation Links
ADVENTRX Pharmaceuticals Announces Closing of Financing
Date:10/9/2009

ion or approval of an ANX-530 NDA; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530, including validating commercial manufacturers and suppliers; the risk that ADVENTRX's common stock will be delisted by the NYSE Amex, including as a result of failing to maintain sufficient stockholders' equity or a sufficient stock price; the risk that the provisions of Delaware General Corporation Law will prohibit ADVENTRX from making the cumulative dividend and other payments due its Series D convertible preferred stock (or to the holders thereof), which may be a breach of its certificate of incorporation or other contractual obligations and expose ADVENTRX to corresponding liability; the risk that ADVENTRX will be unable to raise sufficient additional capital to commercialize ANX-530 or to continue the development of ANX-514; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data may be substandard, or they may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and in the prospectus relating to this offering that was filed with the Securities and Exchange Commission on October 6, 2009. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

SOURCE ADVENTRX Pharmaceuticals, Inc.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
2. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
3. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
4. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
5. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
9. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
10. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
(Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... WASHINGTON, Nov. 1 Multiple myeloma is one,of the ... U.S., but,survival rates have risen dramatically over the past ... to new types of drugs,and aggressive therapeutic interventions such ... studies prepublished online in Blood, the,official journal of the ...
... IRVINE, Calif., Nov. 1 IDM Pharma, Inc.,(Nasdaq: ... data,from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). ... funded cooperative,group study conducted by the Children,s Oncology Group ... of patients originally treated in the Phase,3 trial. The ...
Cached Medicine Technology:Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 2Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 3Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 2IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 3IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 5IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 6
(Date:7/31/2014)... Parsippany, NJ (PRWEB) July 31, 2014 A ... millions of people survive cancer and resume normal lives. This ... American Cancer Society, will affect one in seven American men ... are, has a five-year survival rate of nearly 100% and ... serious illness but most men diagnosed with the disease do ...
(Date:7/31/2014)... USHIO America’s Solid State Lighting ... lighting marketplaces, today announced the launch of its ... users to transform existing, inefficient lamp-based downlights to ... USHIO America’s Uphoria LED downlight retrofit kits fit ... the user to upgrade old incandescent recessed lighting ...
(Date:7/31/2014)... 2014 When guests shop CVS, they’ll find ... to Shea Moisture. And now CVS is adding another acclaimed ... August 1, guests will find G Natural products in CVS ... investment, CEO Roger Gore was inspired to start G’Natural Herbal ... and developing a receding hairline; he tried many products on ...
(Date:7/30/2014)... Calling all runners in the Richmond, VA region. , Tidewater ... monthly Runner’s Injury Clinic at the Glen Allen ... Monday of each month through the end of the year ... December 8. , The clinics run from 5:30 to ... and attire, will receive a complimentary evaluation of running injuries ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 WalkingSticksandCane.com ... Walking Canes. The ladies will love the new European fashions ... Sticks . These sticks and canes are from one from ... England. Each of the styles re unique and offer the ... , The Blackthorn Walking Sticks are some of the rarest ...
Breaking Medicine News(10 mins):Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:USHIO America Introduces Uphoria™ LED Downlight Retrofit Kits 2Health News:CVS Caremark Adds New, Natural Acclaimed Hair Care Line to its Beauty Roster 2Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 2Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 3Health News:European Walking Sticks from WalkingSticksandCane.com 2
... may be sharply divided in their views on many aspects ... in strong agreement when it comes to one of the ... According to results of the American College of Surgeons (ACS) ... support the establishment of a nationwide trauma system - including ...
... Most pregnant women consuming a typical,western diet obtain too ... which is critical for fetal and infant brain,development. This ... panel of nutrition experts summarized in the September 2007,Fats ... called,for pregnant and lactating women to consume at least ...
... a Top ... Priority at Newton-Wellesley, RESTON, Va. and ... announced Newton-Wellesley,s use of,the Isabel decision support system to aid ... the implementation,kicks off an initiative to affirm the quality of ...
... MESA, Ariz., Oct. 3 The Well Life Center ... and healthcare,education, announces the launch of its "10 Healing ... Donations benefit The Arizona,Special Olympics. This session will ... using the 10 universal laws. Discover how to set ...
... Prism Pharmaceuticals,Inc., a privately-held, specialty pharmaceutical company committed ... the appointment of Maurits W. Geerlings, MD, MBA, ... "I am pleased to welcome Dr. Geerlings to ... brings a tremendous amount of relevant,industry experience and ...
... Recently, a man, traveling on,business to Scranton, ... by,ambulance to Moses Taylor Hospital where clinicians identified ... recent seizure, the patient was unable to,communicate his ... registration, a form automatically printed out in the ...
Cached Medicine News:Health News:A nation divided over health care? Not so fast 2Health News:Brain, Eye and Heart Health: Three Reasons to Eat More Omega-3s 2Health News:Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System 2Health News:Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System 3Health News:Moses Taylor Hospital Automates Medication Reconciliation 2
Semi-Automated Chemistry Analyzer with model screen master. The Screen Master incorporates many powerful features in one compact unit. Useful for biochemical investigations, enzymatic, immunoturbidi...
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol for ... chromosome, and histology smears. Our special ... rapidly penetrates cellular elements producing unequaled ... detail and unexcelled brilliance in the ...
Wright-Giemsa Stain Solutions...
Medicine Products: